Feasibility study of a human papillomavirus E6 oncoprotein test for diagnosis of cervical precancer and cancer

Johannes Schweizer, Peter S. Lu, Charles W. Mahoney, Marthe Berard-Bergery, Minh Ho, Valli Ramasamy, Jon E. Silver, Arnima Bisht, Yassine Labiad, Roger B. Peck, Jeanette Lim, Jose Jeronimo, Roslyn Howard, Patti E. Gravitt, Philip E. Castle

Research output: Contribution to journalArticlepeer-review

Abstract

In a feasibility study using a prototype, lateral-flow test for human papillomavirus type 16, 18, and/or 45 (HPV16/18/45) E6 oncoproteins, 51 of 75 (68%; 95% confidence interval [95% CI] of 56 to 78%) of HPV16/18/45 DNA-positive specimens from women with a diagnosis of CIN3+ (cervical intraepithelial neoplasia grade 3+ or cervical cancer) tested positive for HPV16/18/45 E6 oncoprotein. None of 16 (95% CI of 0 to 37%) HPV16/18/45 DNA-positive cervical specimens from women with a negative or CIN1 diagnosis tested positive for HPV16/18/45 E6 oncoprotein.

Original languageEnglish (US)
Pages (from-to)4646-4648
Number of pages3
JournalJournal of clinical microbiology
Volume48
Issue number12
DOIs
StatePublished - Dec 2010

ASJC Scopus subject areas

  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Feasibility study of a human papillomavirus E6 oncoprotein test for diagnosis of cervical precancer and cancer'. Together they form a unique fingerprint.

Cite this